Savara to present aPAP treatment study at medical congresses

LANGHORNE, Pa. - Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company specializing in rare respiratory diseases with a market capitalization of $574.6 million, is set to present data from a recent Phase 3 clinical trial at two upcoming medical congresses. The trial focuses on molgramostim, an investigational treatment for autoimmune pulmonary alveolar proteinosis (aPAP). According to InvestingPro data, the company maintains a strong financial position with more cash than debt on its balance sheet.

The data will be showcased at the 65th Congress of the German Society of Pneumology in Leipzig, Germany, on Sunday, and at the 65th Annual Meeting of the Japanese Respiratory Society in Tokyo, Japan, on Tuesday. The presentations will detail the effectiveness of inhaled molgramostim in improving pulmonary gas exchange, quality of life, and exercise capacity in patients with aPAP. While the company is not yet profitable, analyst price targets ranging from $3 to $16 suggest significant potential upside if the treatment proves successful. Get more detailed analysis and insights with a InvestingPro subscription, which includes comprehensive research reports on over 1,400 stocks.

aPAP is a rare lung disease where a build-up of surfactant occurs due to an inability of alveolar macrophages to clear it, leading to difficulty in breathing and other serious complications. Molgramostim, a recombinant human granulocyte-macrophage colony-stimulating factor, aims to stimulate these macrophages to function correctly.

The presentations, one by Dr. Francesco Bonella in Germany and another by Dr. Yoshikazu Inoue in Japan, will provide insights from the IMPALA-2 Phase 3 trial. Post-discussion, these presentations will be accessible on Savara's corporate website under the Congresses & Publications section.

Savara's focus remains on addressing unmet needs in rare respiratory diseases, with molgramostim being their lead program currently in Phase 3 development. The treatment is administered via a specialized nebulizer system designed for large molecule inhalation.

This news is based on a press release statement and aims to inform on the upcoming professional discourse regarding molgramostim's trial results in the medical community. Further information about the congresses can be found on their respective websites. With a current ratio of 13.73 and a conservative beta of 0.52, InvestingPro analysis indicates Savara maintains strong financial health despite being in the development stage. The company's next earnings report is scheduled for May 8, 2025.

In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for autoimmune pulmonary alveolar proteinosis (aPAP). The company is seeking a Priority Review, which could expedite the FDA's decision-making process. Savara is preparing for a potential commercial launch of MOLBREEVI in early 2026, pending approval. Meanwhile, analysts at H.C. Wainwright and JMP Securities have maintained positive outlooks on Savara, with price targets of $6.00 and $9.00, respectively, based on the anticipated approval and market potential of MOLBREEVI.

Savara has also terminated its sales agreement with Evercore Group L.L.C., ending their arrangement for at-the-market offerings of common stock. This decision does not incur any penalties for the company. Additionally, retrospective data from European single-patient access programs suggest significant therapeutic benefits of molgramostim, the active compound in MOLBREEVI, for aPAP patients. The drug has shown promise in improving lung function and reducing the need for whole lung lavage, a current treatment for aPAP. Savara is set to continue its regulatory pursuits with a Marketing Authorization Application in Europe by the end of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.